Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lumos Diagnostics
Lumos Diagnostics is considering an appeal of the agency’s decision to refuse market clearance for its FebriDX test.
A panel discussed opportunities and challenges in POC testing beyond the pandemic, including the consumer-centric health care environment and continued innovation.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing